|

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

RECRUITINGSponsored by National Cancer Institute (NCI)
Actively Recruiting
SponsorNational Cancer Institute (NCI)
Started2010-04-21
Eligibility
Age4 Weeks+
Healthy vol.Accepted
Locations5 sites

Summary

Background: \- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: \- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers. Eligibility: * Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age. * Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults. Design: * Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study. * No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.

Eligibility

Age: 4 Weeks+Healthy volunteers accepted
* SUBJECT INCLUSION CRITERIA:

Pediatric or adult subjects with one of the following:

* Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;
* Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;
* Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;
* Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.
* Human samples, specimens and data collected on IRB approved protocols that are now closed
* Ability of subject, Legally Authorized Representative (LAR), or parent/legal guardian of children \<=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.

Inclusion Criteria for Social and Behavioral Outcome Interviews:

* Parent/caregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.
* Must be able to give consent and sign the informed consent document.
* Able to understand the English language.

EXCLUSION CRITERIA:

None

Conditions6

CancerEndocrine TumorsNeuroblastomaRenal CancerRetinoblastomaSarcoma

Locations5 sites

District of Columbia

1 site
Children's National Medical Center
Washington D.C., District of Columbia, 20010

Florida

1 site
Children's Hospital of Orange County (CHOC Children's)
Orange, Florida, 92613

Maryland

1 site
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)800-411-1222ccopr@nih.gov

New York

1 site
Tisch Cancer Institute, Mount Sinai Medical Center
New York, New York, 10029-0574

North Carolina

1 site
Carolinas Medical Center/Levine Children's Hospital
Charlotte, North Carolina, 28203

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.